Cat. No. | Product name | CAS No. |
DC8009 |
CEP-37440
Featured
CEP-37440 is a novel potent and selective Dual FAK/ALK inhibitor with IC50 s of 2.3 nM (FAK) and 120 nM(ALK cellular IC50 in 75% human plasma). |
1391712-60-9 |
DC7695 |
Defactinib (VS-6063, PF-04554878)
Featured
Defactinib is a potent, selective, and orally active FAK inhibitor with demonstrated tolerability and preliminary clinical activity working as a single agent as well as in combination with paclitaxel. |
1073154-85-4 |
DC10100 |
Defactinib hydrochloride
Featured
Defactinib is a potent, selective, and orally active FAK inhibitor with demonstrated tolerability and preliminary clinical activity working as a single agent as well as in combination with paclitaxel. |
1073160-26-5 |
DC8331 |
GSK2256098
Featured
GSK2256098 is small molecule FAK kinase inhibitor. |
1224887-10-8 |
DC9787 |
NAMI-A
NAMI-A is a ruthenium anticancer agent and a metastasis inhibitor. |
201653-76-1 |
DC4106 |
PF573228
Featured
PF 573228 is a inhibitor of FAK with IC50 of 4 nM. |
869288-64-2 |
DC3168 |
PF-562271 PHSO3H SALT
Featured
PF-00562271 is the benzenesulfonate salt of PF-562271, which is a potent, ATP-competitive, reversible inhibitor of FAK and Pyk2 with IC50 of 1.5 nM and 14 nM, respectively. |
939791-38-5 |
DC7941 |
PF-431396
Featured
PF-431396 is dual focal adhesion kinase (FAK) and proline-rich tyrosine kinase 2 (PYK2) inhibitor , PF-431396 has a Kd value of 445 nM for BRD4. |
717906-29-1 |
DC8526 |
PF4618433
Featured
PF-4618433 shows improved PYK2 potency, reduced p38 activity, and superior overall selectivity relative to the prototype BIRB796. |
1166393-85-6 |
DC3169 |
PF-562271
Featured
PF-562271 is a potent, ATP-competitive, reversible inhibitor of FAK and Pyk2 with IC50 of 1.5 nM and 14 nM, respectively. |
717907-75-0 |
DC7241 |
PND-1186
Featured
PND-1186 is a potent FAK inhibitor with IC50 of 1.5 nM. |
1061353-68-1 |
DC7885 |
NVP-TAE226
Featured
TAE226 (NVP-TAE226) is a potent FAK inhibitor with IC50 of 5.5 nM and modestly potent to Pyk2, ~10- to 100-fold less potent against InsR, IGF-1R, ALK, and c-Met. |
761437-28-9 |
DC8376 |
TAS-301
Featured
TAS-301 is an inhibitor of smooth muscle cell migration and proliferation. |
193620-69-8 |
DC9446 |
Y15
Featured
Y15 is a novel small molecule FAK phosphorylation inhibitor; specifically block phosphorylation of Y397-FAK and total phosphorylation of FAK. |
4506-66-5 |
DC40366 |
Petunidin chloride
Petunidin chloride is an O-methylated anthocyanidin derived from delphinidin that imparts blue-red pigments to flowers, fruits, and red wine. Petunidin chloride binds with and suppresses the activity of focal adhesion kinase and to inhibit platelet-derived growth factor-induced aortic smooth muscle cell migration, which may confer a protective effect against atherosclerosis. |
1429-30-7 |
DC42457 |
PND-1186 hydrochloride
PND-1186 hydrochloride (VS-4718 hydrochloride) is a potent, highly-specific and reversible of FAK with an IC50 of 1.5 nM. PND-1186 hydrochloride selectively promotes tumor cell apoptosis. |
1356154-94-3 |
DC46369 |
GSK215
GSK215 is a potent and selective PROTAC focal adhesion kinase (FAK) degrader. GSK215 is designed by a binder for the VHL E3 ligase and the FAK inhibitor VS-4718. GSK215 induces rapid and prolonged FAK degradation, giving a long-lasting effect on FAK levels and a marked pharmacokinetic/pharmacodynamics (PK/PD) disconnect. |
|
DC48742 |
YH-306
YH-306 is a candidate drug in preventing growth and metastasis of colorectal cancer by modulating FAK signalling pathway. |
1373764-75-0 |
DC49068 |
AMP-945
AMP-945 is an inhibitor of the enzyme focal adhesion kinase (FAK). |
1393653-34-3 |
DC50220 |
FAK-IN-2
FAK-IN-2 is a potent and orally active focal adhesion kinase (FAK) inhibitor, with anticancer activity (FAK IC50= 35 nM). FAK-IN-2 covalently inhibits the autophosphorylation of FAK in a dose-dependent manner, and inhibits the clone formation and migration of tumor cells, inducing apoptosis. |
|
DC70256 |
BJG-03-025
BJG-03-025 is a potent, highly selective FAK tyrosine kinase inhibitor with biochemical IC50 of 20.2 nM.BJG-03-025 demonstrates excellent kinome selectivity was profiled by KINOMEscan screening, PLK1 proved to be a false positive with IC50 of 8.3 uM, 100-300-fold selective for FAK.BJG-03-025 displays antiproliferative activity in three-dimensional (3D)-breast and gastric cancer models and impacts cellular signaling and migration.BJG-03-025 decreased phosphorylated FAK (pFAK Y397) in gastric cancer CDH1–/–RHOAY42C/+ organoid model, decreased aberrant signaling and proliferation of gastric cancer organoids. |
2553213-90-2 |